Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use—A Prospective Real-Life Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use—A Prospective Real-Life Study ; volume:31 ; number:5 ; day:29 ; month:1 ; year:2024 ; pages:2892-2901 ; date:5.2024
Annals of surgical oncology ; 31, Heft 5 (29.1.2024), 2892-2901, 5.2024
- Creator
-
Paiella, Salvatore
Malleo, Giuseppe
Lionetto, Gabriella
Cattelani, Alice
Casciani, Fabio
Secchettin, Erica
De Pastena, Matteo
Bassi, Claudio
Salvia, Roberto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-024-14951-4
- URN
-
urn:nbn:de:101:1-2406211159206.467020418321
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Paiella, Salvatore
- Malleo, Giuseppe
- Lionetto, Gabriella
- Cattelani, Alice
- Casciani, Fabio
- Secchettin, Erica
- De Pastena, Matteo
- Bassi, Claudio
- Salvia, Roberto
- SpringerLink (Online service)
Other Objects (12)
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Upfront surgical resection for primary bone tumors: rationale and potential benefits
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma